Shire agrees to supply Adderall XR generic to Sandoz
LONDON (Reuters) - Pharmaceutical company Shire said on Monday it had agreed to supply an authorized generic version of Adderall XR, its drug to treat hyperactivity, to Sandoz.
Adderall, an amphetamine, is available in instant release and extended release formulations. Shire now only produces the extended version, for which it retains patent rights, and sales of the drug have been falling since a generic version became available in 2009.
However, the drug still generated sales of $81.4 million for Shire in the third quarter of the year.
Under the agreement, Sandoz, the generic arm of Novartis, will exclusively sell the authorized generic version of Adderall XR supplied by Shire from July 1, 2016 in the United States, Shire said, adding it would receive a royalty on sales.
- Israel rejects ceasefire plan, source says, as death toll nears 850 |
- White House aide says Republicans might try for Obama impeachment
- First Ebola victim in Sierra Leone capital on the run
- Bad weather seen as probable cause of Air Algerie crash
- EU edges to economic sanctions on Russia but narrows scope |
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video